Key facts
- This page summarizes Eric Trachtenberg's Form 4 filing for KALA BIO, Inc. (KALA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2024, 16:07.
Eric Trachtenberg - 04 Jan 2024 Form 4 Insider Report for KALA BIO, Inc. (KALA)
- Reporting relationship
- Chief Legal Officer, Chief Compliance Officer and Secretary
- Issuer ticker
- KALA
- Reported as of
- 04 Jan 2024
- Net transaction value
- -$8,270
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2024, 16:07:04 UTC
- Prior SEC filing
- 23 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Trachtenberg
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Trachtenberg filed Form 4 for KALA BIO, Inc. (KALA) on 05 Jan 2024.
Change
- Previous filing in this sequence was filed on 23 Jun 2023.
- Current net transaction value: -$8,270.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KALA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,600
- Change %
- +7.1%
- Price
- $0.000000
- Shares after
- 69,293
- Date
- 04 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
KALA
transaction
Common Stock
Sale
- Transaction value
- $8,270
- Shares
- -1,227
- Change %
- -1.8%
- Price
- $6.74
- Shares after
- 68,066
- Date
- 04 Jan 2024
- Ownership
- Direct
- Footnotes
- F3, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KALA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +20,500
- Change %
- Price
- $0.000000
- Shares after
- 20,500
- Date
- 04 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,500
- Exercise price
- $7.00
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027.
Footnote F2
Includes 67,474 unvested RSUs.
Footnote F3
This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021.
Footnote F4
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Footnote F5
Includes 64,149 unvested RSUs.
Footnote F6
This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer.
SEC remarks
Chief Legal Officer, Chief Compliance Officer and Secretary